|
1
|
Zhao C, Tella SH, Del Rivero J,
Kommalapati A, Ebenuwa I, Gulley J, Strauss J and Brownell I:
Anti-PD-L1 treatment induced central diabetes insipidus. J Clin
Endocrinol Metab. 103:365–369. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Husebye ES, Castinetti F, Criseno S,
Curigliano G, Decallonne B, Fleseriu M, Higham CE, Lupi I, Paschou
SA, Toth M, et al: Endocrine-related adverse conditions in patients
receiving immune checkpoint inhibition-an ESE clinical practice
guideline. Eur J Endocrinol. (EJE-22-0689)(2022): (Epub ahead of
print).
|
|
3
|
Di Dalmazi G, Ippolito S, Lupi I and
Caturegli P: Hypophysitis induced by immune checkpoint inhibitors:
A 10-year assessment. Expert Rev Endocrinol Metab. 14:381–398.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Fernandes S, Varlamov EV, McCartney S and
Fleseriu M: A novel etiology of hypophysitis: Immune checkpoint
inhibitors. Endocrinol Metab Clin North Am. 49:387–399.
2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Vaddepally RK, Kharel P, Pandey R, Garje R
and Chandra AB: Review of indications of FDA-approved immune
checkpoint inhibitors per NCCN guidelines with the level of
evidence. Cancers (Basel). 12(738)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mutter CM, Smith T, Menze O, Zakharia M
and Nguyen H: Diabetes insipidus: Pathogenesis, diagnosis, and
clinical management. Cureus. 13(e13523)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Dillard T, Yedinak CG, Alumkal J and
Fleseriu M: Anti-CTLA-4 antibody therapy associated autoimmune
hypophysitis: Serious immune related adverse events across a
spectrum of cancer subtypes. Pituitary. 13:29–38. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nallapaneni NN, Mourya R, Bhatt VR,
Malhotra S, Ganti AK and Tendulkar KK: Ipilimumab-induced
hypophysitis and uveitis in a patient with metastatic melanoma and
a history of ipilimumab-induced skin rash. J Natl Compr Cancer
Netw. 12:1077–1081. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gunawan F, George E and Roberts A:
Combination immune checkpoint inhibitor therapy nivolumab and
ipilimumab associated with multiple endocrinopathies. Endocrinol
Diabetes Metab Case Reports. 2018:17–0146. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tshuma N, Glynn N, Evanson J, Powles T and
Drake WM: Hypothalamitis and severe hypothalamic dysfunction
associated with anti-programmed cell death ligand 1 antibody
treatment. Eur J Cancer. 104:247–249. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Deligiorgi MV, Siasos G, Vergadis C and
Trafalis DT: Central diabetes insipidus related to anti-programmed
cell-death 1 protein active immunotherapy. Int Immunopharmacol.
83(106427)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Barnabei A, Carpano S, Chiefari A,
Bianchini M, Lauretta R, Mormando M, Puliani G, Paoletti G,
Appetecchia M and Torino F: Case report: Ipilimumab-induced
panhypophysitis: An infrequent occurrence and literature review.
Front Oncol. 10(582394)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Grami Z, Manjappachar N and Reddy DR: 323:
Diabetes insipidus in checkpoint inhibitor treatment and acute
myeloid leukemia. Crit Care Med. 48(144)2020.
|
|
14
|
Yu M, Liu L, Shi P, Zhou H, Qian S and
Chen K: Anti-PD-1 treatment-induced immediate central diabetes
insipidus: A case report. Immunotherapy. 13:1255–1260.
2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fosci M, Pigliaru F, Salcuni AS, Ghiani M,
Cherchi MV, Calia MA, Loviselli A and Velluzzi F: Diabetes
insipidus secondary to nivolumab-induced neurohypophysitis and
pituitary metastasis. Endocrinol Diabetes Metab Case Rep.
2021:20–0123. 2021.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print).
|
|
16
|
Brilli L, Calabrò L, Campanile M, Pilli T,
Agostinis C, Cerase A, Maio M and Castagna MG: Permanent diabetes
insipidus in a patient with mesothelioma treated with
immunotherapy. Arch Endocrinol Metab. 64:483–486. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bai X, Chen X, Wu X, Huang Y, Zhuang Y,
Chen Y, Feng C and Lin X: Immune checkpoint inhibitor-associated
pituitary adverse events: An observational, retrospective,
disproportionality study. J Endocrinol Invest. 43:1473–1483.
2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gubbi S, Hannah-Shmouni F, Koch CA,
Verbalis JG, Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder
WW, Dhatariya K (eds), et al: Diagnostic testing for diabetes
insipidus. In: Endotext [Internet]. MDText.com, Inc., South
Dartmouth, MA, 2000.
|
|
19
|
Christ-Crain M, Winzeler B and Refardt J:
Diagnosis and management of diabetes insipidus for the internist:
An update. J Intern Med. 290:73–87. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Terán Brage E, Heras Benito M, Navalón
Jiménez MB, Vidal Tocino R, del Barco Morillo E and Fonseca Sánchez
E: Severe hyponatremia masking central diabetes insipidus in a
patient with a lung adenocarcinoma. Case Rep Oncol. 15:91–98.
2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Amereller F, Deutschbein T, Joshi M,
Schopohl J, Schilbach K, Detomas M, Duffy L, Carroll P, Papa S and
Störmann S: Differences between immunotherapy-induced and primary
hypophysitis-a multicenter retrospective study. Pituitary.
25:152–158. 2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Di Iorgi N, Napoli F, Allegri AE, Olivieri
I, Bertelli E, Gallizia A, Rossi A and Maghnie M: Diabetes
insipidus-diagnosis and management. Horm Res Paediatr. 77:69–84.
2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Di Nunno V, Mollica V, Corcioni B,
Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E,
Ardizzoni A and Massari F: Clinical management of a pituitary gland
metastasis from clear cell renal cell carcinoma. Anticancer Drugs.
29:710–715. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Javanbakht A, D'Apuzzo M, Badie B and
Salehian B: Pituitary metastasis: A rare condition. Endocr Connect.
7:1049–1057. 2018.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print).
|
|
25
|
Faje A: Immunotherapy and hypophysitis:
Clinical presentation, treatment, and biologic insights. Pituitary.
19:82–92. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ryder M, Callahan M, Postow MA, Wolchok J
and Fagin JA: Endocrine-related adverse events following ipilimumab
in patients with advanced melanoma: A comprehensive retrospective
review from a single institution. Endocr Relat Cancer. 21:371–381.
2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Byun DJ, Wolchok JD, Rosenberg LM and
Girotra M: Cancer immunotherapy-immune checkpoint blockade and
associated endocrinopathies. Nat Rev Endocrinol. 13:195–207.
2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bellastella G, Maiorino MI, Bizzarro A,
Giugliano D, Esposito K, Bellastella A and De Bellis A:
Revisitation of autoimmune hypophysitis: Knowledge and
uncertainties on pathophysiological and clinical aspects.
Pituitary. 19:625–642. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Iwama S, De Remigis A, Callahan MK, Slovin
SF, Wolchok JD and Caturegli P: Pituitary expression of CTLA-4
mediates hypophysitis secondary to administration of CTLA-4
blocking antibody. Sci Transl Med. 6(230ra45)2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Caturegli P, Di Dalmazi G, Lombardi M,
Grosso F, Larman HB, Larman T, Taverna G, Cosottini M and Lupi I:
Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein
4 blockade: Insights into pathogenesis from an autopsy series. Am J
Pathol. 186:3225–3235. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY,
Kaiser UB, Woodmansee WW, Reardon DA, Freeman GJ, Fecci PE, et al:
Increased expression of programmed death ligand 1 (PD-L1) in human
pituitary tumors. Oncotarget. 7(76565)2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Priya G, Kalra S, Dasgupta A and Grewal E:
Diabetes insipidus: A pragmatic approach to management. Cureus.
13(e12498)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Christ-Crain M and Fenske W: Copeptin in
the diagnosis of vasopressin-dependent disorders of fluid
homeostasis. Nat Rev Endocrinol. 12:168–176. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Christ-Crain M, Hoorn EJ, Sherlock M,
Thompson CJ and Wass J: Endocrinology in the time of COVID-19-2021
updates: The management of diabetes insipidus and hyponatraemia.
Eur J Endocrinol. 185:G35–G42. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Garrahy A, Moran C and Thompson CJ:
Diagnosis and management of central diabetes insipidus in adults.
Clin Endocrinol (Oxf). 90:23–30. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Fenske W, Refardt J, Chifu I, Schnyder I,
Winzeler B, Drummond J, Ribeiro-Oliveira A Jr, Drescher T, Bilz S,
Vogt DR, et al: A copeptin-based approach in the diagnosis of
diabetes insipidus. N Engl J Med. 379:428–439. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Winzeler B, Cesana-Nigro N, Refardt J,
Vogt DR, Imber C, Morin B, Popovic M, Steinmetz M, Sailer CO,
Szinnai G, et al: Arginine-stimulated copeptin measurements in the
differential diagnosis of diabetes insipidus: A prospective
diagnostic study. Lancet. 394:587–595. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Timper K, Fenske W, Kühn F, Frech N, Arici
B, Rutishauser J, Kopp P, Allolio B, Stettler C, Müller B, et al:
Diagnostic accuracy of copeptin in the differential diagnosis of
the polyuria-polydipsia syndrome: A prospective multicenter study.
J Clin Endocrinol Metab. 100:2268–2274. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Brooks BS, el Gammal T, Allison JD and
Hoffman WH: Frequency and variation of the posterior pituitary
bright signal on MR images. Am J Roentgenol. 153:1033–1038.
1989.PubMed/NCBI
|
|
40
|
Corsello SM, Barnabei A, Marchetti P, De
Vecchis L, Salvatori R and Torino F: Endocrine side effects induced
by immune checkpoint inhibitors. J Clin Endocrinol Metab.
98:1361–1375. 2013.PubMed/NCBI View Article : Google Scholar
|
